论文部分内容阅读
Background: Ipriflavone (IP), a synthesized derivative of isoflavone, has become an over-the-counter drug for prevention of osteoporosis (OP) since 1989 in over 22 countries.Although clinical trials have proved that IP is beneficial for the prevention and treatment of osteoporosis, its efficacy and safety have not been confirmed due to some contradictory reports.With the wide acceptance of IP in osteoporotic women, it is therefore necessary to give a systematic review and meta-analysis for further evaluation.